Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial

Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials

(2022) Alex C. Spyropoulos et al.   CIRCULATION

ISTH guidelines for antithrombotic treatment in COVID ‐19

(2022) Sam Schulman et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial

(2022) Ingrid M Bistervels et al.   LANCET

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit

(2021) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID‐19: A multi‐center, open‐label, randomized controlled trial

(2021) Usha S. Perepu et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

(2021)   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

(2021)   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19

(2021) Alex C. Spyropoulos et al.   JAMA Internal Medicine

Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China

(2020) Qingxian Cai et al.   DIABETES CARE

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

(2020) Behnood Bikdeli et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Incidence of venous thromboembolism in hospitalized patients with COVID‐19

(2020) Saskia Middeldorp et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Definition of major bleeding: Prognostic classification

(2020) Laura Franco et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

(2020) F.A. Klok et al.   THROMBOSIS RESEARCH

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19

(2020) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anticoagulant interventions in hospitalized patients with COVID‐19: A scoping review of randomized controlled trials and call for international collaboration

(2020) Tobias Tritschler et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies

(2020) Alessandro Di Minno et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

(2019) Stavros V Konstantinides et al.   EUROPEAN HEART JOURNAL

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

(2015) S. Kaatz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery

(2014) Céline Chapelle et al.   THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients

(2013) T.-F. Wang et al.   THROMBOSIS AND HAEMOSTASIS